ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
2,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
3,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
3,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
4,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
4,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
4,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
5,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
5,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
6,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
6,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
6,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
7,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
7,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
7,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
8,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
9,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
10,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
11,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
12,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
13,1,Agnosia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
13,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
13,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
13,4,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
13,5,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
13,6,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
13,7,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
13,8,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
13,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
13,10,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
13,11,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
13,12,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
13,13,Personality disorder,Personality disorders NEC,Personality disorders and disturbances in behaviour,Psych,N
13,14,Somatic symptom disorder,Somatic symptom disorders,Somatic symptom and related disorders,Psych,N
13,15,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
14,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
15,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
16,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
16,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
16,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
17,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
18,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
18,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
19,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
19,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
19,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
19,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
19,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
20,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
20,3,Inflammation,Inflammations,General system disorders NEC,Genrl,N
21,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
22,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
22,2,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
22,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
22,4,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
23,1,Headache,Headaches NEC,Headaches,Nerv,N
23,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
23,3,Sinus pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
24,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
24,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
24,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
24,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
25,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
25,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
26,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
26,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
26,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
27,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
27,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
27,3,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
27,4,Headache,Headaches NEC,Headaches,Nerv,N
27,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
28,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
29,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
30,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
30,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
31,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
31,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
32,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
32,2,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
33,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
34,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
35,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
36,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
36,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
37,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
38,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
39,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
39,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
39,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
39,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
39,5,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
40,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
40,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
40,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
41,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
42,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
43,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
43,2,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
44,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
44,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
45,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
46,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
46,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
46,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
46,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
46,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
47,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
47,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
48,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
48,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
49,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
50,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
51,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
51,2,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
52,1,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
53,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
54,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
54,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
54,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
55,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
56,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
57,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
57,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
58,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
58,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
58,3,Tachyphylaxis,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
59,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
59,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
60,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
61,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
61,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
61,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
62,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
62,2,Headache,Headaches NEC,Headaches,Nerv,N
62,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
62,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
63,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
64,1,Polyarthritis,Arthropathies NEC,Joint disorders,Musc,N
65,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
65,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
65,3,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
66,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
66,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
67,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
68,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
69,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
70,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
70,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
70,3,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
70,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
71,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
71,2,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
71,3,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
71,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
72,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
72,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
73,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
73,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
74,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
74,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
75,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
76,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
77,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
78,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
78,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
79,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
80,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
81,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
82,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
83,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
83,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
83,3,Headache,Headaches NEC,Headaches,Nerv,N
84,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
85,1,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
86,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
87,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
88,1,Complication associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
88,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
89,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
89,2,Gingival pain,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
89,3,Gingival swelling,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
89,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
89,5,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
89,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
89,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
90,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
90,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
91,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
92,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
92,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
93,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
94,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
95,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
96,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
96,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
97,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
98,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
99,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
99,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
100,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
101,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
101,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
102,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
102,2,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
102,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
103,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
104,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
104,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
105,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
105,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
106,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
106,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
107,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
107,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
108,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
109,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
110,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
111,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
112,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
112,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
113,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
114,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
114,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
115,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
116,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
116,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
117,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
118,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
119,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
119,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
120,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
120,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
121,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
121,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
121,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
122,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
122,2,Headache,Headaches NEC,Headaches,Nerv,N
122,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
123,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
124,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
125,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
126,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
126,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
126,3,Furuncle,Staphylococcal infections,Bacterial infectious disorders,Infec,N
126,4,Headache,Headaches NEC,Headaches,Nerv,N
126,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
126,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
126,7,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
127,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
128,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
129,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
129,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
129,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
129,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
130,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
130,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
130,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
130,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
130,5,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
131,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
132,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
132,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
132,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
133,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
134,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
135,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
135,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
136,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
136,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
137,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
137,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
137,3,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
137,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
137,5,Coordination abnormal,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
137,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
137,7,Derealisation,Perception disturbances NEC,Disturbances in thinking and perception,Psych,N
137,8,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
137,9,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
137,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
137,11,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
137,12,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
137,13,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
137,14,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
137,15,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
137,16,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
137,17,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
137,18,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
137,19,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
137,20,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
138,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
139,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
139,2,Injection site oedema,Injection site reactions,Administration site reactions,Genrl,N
139,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
139,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
140,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
140,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
141,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
141,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
142,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
142,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
143,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
144,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
145,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
145,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
145,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
145,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
145,5,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
146,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
146,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
147,1,Hypokinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
147,2,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
148,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
148,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
149,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
150,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
150,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
151,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
152,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
153,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
153,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
153,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
154,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
154,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
154,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
154,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
154,5,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
154,6,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
154,7,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
154,8,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
154,9,Hangover,Feelings and sensations NEC,General system disorders NEC,Genrl,N
154,10,Headache,Headaches NEC,Headaches,Nerv,N
154,11,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
154,12,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
154,13,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
154,14,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
155,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
155,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
156,1,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
156,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
156,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
156,4,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
156,5,Psychiatric symptom,Psychiatric symptoms NEC,Psychiatric and behavioural symptoms NEC,Psych,N
157,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
158,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
158,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
159,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
160,1,Aplasia cutis congenita,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
161,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
162,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
163,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
164,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
164,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
165,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
166,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
166,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
166,3,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
167,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
167,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
167,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
167,4,Thinking abnormal,Thinking disturbances,Disturbances in thinking and perception,Psych,N
168,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
168,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
168,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
169,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
169,2,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,N
170,1,Foetal heart rate deceleration abnormality,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
171,1,Cluster headache,Headaches NEC,Headaches,Nerv,N
171,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
172,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
172,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
173,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
174,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
174,2,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
174,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
175,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
175,2,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
175,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
176,1,Device failure,Device issues NEC,Device issues,Prod,N
176,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
177,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
177,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
177,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
178,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
178,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
179,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
179,2,Tension headache,Headaches NEC,Headaches,Nerv,N
180,1,Anencephaly,Cerebral disorders congenital,Neurological disorders congenital,Cong,N
181,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
181,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
181,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
182,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
183,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
184,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
185,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
185,2,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
185,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
186,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
187,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
187,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
187,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
188,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
188,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
189,1,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
190,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
191,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
192,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
192,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
192,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
193,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
193,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
193,3,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
193,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
193,5,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
194,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
195,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
196,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
196,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
196,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
196,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
197,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
198,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
199,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
200,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
200,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
200,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
200,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
201,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
201,2,Device leakage,Device issues NEC,Device issues,Prod,N
202,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
202,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
202,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
203,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
203,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
204,1,Complication associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
204,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
204,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
204,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
205,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
205,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
205,3,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
205,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
205,5,Skin striae,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
206,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
207,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
207,2,Device failure,Device issues NEC,Device issues,Prod,N
207,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
208,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
209,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
209,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
209,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
210,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
210,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
210,3,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
211,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
211,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
211,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
212,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
212,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
212,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
212,4,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
212,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
213,1,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
213,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
213,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
213,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
213,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
214,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
214,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
214,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
215,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
215,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
216,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
216,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
217,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
218,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
219,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
220,1,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
220,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
220,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
221,1,Stevens-Johnson syndrome,Bullous conditions,Epidermal and dermal conditions,Skin,N
222,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
223,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
223,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
224,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
224,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
224,3,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
224,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
224,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
225,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
226,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
226,2,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
226,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
226,4,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
226,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
226,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
226,7,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
227,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
228,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
228,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
229,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
229,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
230,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
230,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
230,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
231,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
231,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
231,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
231,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
231,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
232,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
233,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
233,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
234,1,Small for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
235,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
236,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
236,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
236,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
237,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
238,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
238,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
238,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
238,4,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
239,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
239,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
239,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
239,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
240,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
240,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
240,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
240,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
241,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
241,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
241,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
242,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
243,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
244,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
244,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
244,3,Vitreous floaters,"Choroid and vitreous structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
245,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
246,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
247,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
247,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
247,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
248,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
248,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
248,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
249,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
250,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
250,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
250,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
251,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
251,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
251,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
252,1,Injection site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
252,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
253,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
253,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
254,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
255,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
255,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
255,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
255,4,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
255,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
256,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
256,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
257,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
258,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
259,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
259,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
260,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
260,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
261,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
261,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
261,3,Malabsorption from injection site,Injection site reactions,Administration site reactions,Genrl,N
262,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
262,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
263,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
264,1,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
265,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
265,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
266,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
266,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
267,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
268,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
269,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
269,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
269,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
269,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
269,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
269,6,Premature labour,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
270,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
271,1,Headache,Headaches NEC,Headaches,Nerv,N
272,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
272,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
272,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
273,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
273,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
274,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
274,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
274,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
274,4,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
274,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
274,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
275,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
276,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
277,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
278,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
279,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
279,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
279,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
280,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
281,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
281,2,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
282,1,Biopsy,Histopathology procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
282,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
282,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
282,4,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
282,5,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
282,6,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
282,7,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
282,8,Haemorrhagic urticaria,Urticarias,Angioedema and urticaria,Skin,N
282,9,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
282,10,Neuropathic ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
282,11,Nikolsky's sign,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
282,12,Oral disorder,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
282,13,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
282,14,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
282,15,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
282,16,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
282,17,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
282,18,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
282,19,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
282,20,Varicella zoster virus infection,Herpes viral infections,Viral infectious disorders,Infec,N
283,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
283,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
284,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
284,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
285,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
285,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
285,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
285,4,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
285,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
285,6,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
285,7,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
285,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
285,9,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
286,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
286,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
286,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
287,1,Cardiac death,Death and sudden death,Fatal outcomes,Genrl,Y
287,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
287,3,Generalised anxiety disorder,Anxiety disorders NEC,Anxiety disorders and symptoms,Psych,N
288,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
289,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
290,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
290,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
290,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
291,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
291,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
292,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
293,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
294,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
294,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
294,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
295,1,Crying,General signs and symptoms NEC,General system disorders NEC,Genrl,N
295,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
296,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
297,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
297,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
298,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
298,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
298,3,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
299,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
299,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
299,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
300,1,Neuropathic arthropathy,Osteoarthropathies,Joint disorders,Musc,N
301,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
301,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
301,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
302,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
302,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
302,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
302,4,Headache,Headaches NEC,Headaches,Nerv,N
302,5,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
302,6,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
302,7,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
302,8,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
302,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
302,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
303,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
303,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
304,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
304,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
305,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
305,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
306,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
306,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
306,3,Premature rupture of membranes,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
307,1,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
307,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
307,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
307,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
308,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
308,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
308,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
309,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
310,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
310,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
310,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
311,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
311,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
312,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
312,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
312,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
313,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
313,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
313,3,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
313,4,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
314,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
315,1,Cellulite,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
316,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
316,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
317,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
317,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
318,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
319,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
320,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
321,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
321,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
321,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
322,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
322,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
322,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
323,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
324,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
324,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
324,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
324,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
325,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
325,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
325,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
326,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
326,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
327,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
327,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
328,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
328,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
329,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
329,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
330,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
330,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
331,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
331,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
331,3,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
332,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
332,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
332,3,Premature rupture of membranes,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
333,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
333,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
333,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
334,1,Developmental hip dysplasia,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
334,2,Foetal distress syndrome,Foetal complications NEC,Foetal complications,Preg,N
334,3,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
334,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
334,5,Inguinal hernia,Inguinal hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
334,6,Jaundice neonatal,Neonatal hepatobiliary disorders,Neonatal and perinatal conditions,Preg,N
334,7,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
334,8,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
335,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
335,2,Device leakage,Device issues NEC,Device issues,Prod,N
335,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
335,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
336,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
336,2,Device leakage,Device issues NEC,Device issues,Prod,N
336,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
337,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
337,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
337,3,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
338,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
339,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
339,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
340,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
340,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
340,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
341,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
341,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
342,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
342,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
342,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
342,4,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
342,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
342,6,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
342,7,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
342,8,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
342,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
342,10,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
343,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
344,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
345,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
346,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
347,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
348,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
349,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
349,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
349,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
349,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
350,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
350,2,Neurological symptom,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
351,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
351,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
351,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
351,4,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
352,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
353,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
353,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
353,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
354,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
354,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
354,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
354,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
355,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
355,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
355,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
355,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
355,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
355,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
356,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
356,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
357,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
357,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
358,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
358,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
358,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
359,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
359,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
359,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
359,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
360,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
360,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
360,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
360,4,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
360,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
361,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
361,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
361,3,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
362,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
363,1,Caudal regression syndrome,Musculoskeletal and connective tissue disorders of spine congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
364,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
364,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
365,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
366,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
366,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
366,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
367,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
368,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
368,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
368,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
368,4,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
369,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
369,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
369,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
369,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
370,1,Apparent death,General signs and symptoms NEC,General system disorders NEC,Genrl,N
370,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
371,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
371,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
371,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
372,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
373,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
373,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
373,3,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
373,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
373,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
373,6,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
374,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
375,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
375,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
376,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
376,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
377,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
378,1,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
379,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
379,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
380,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
380,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
381,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
382,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
382,2,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
382,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
382,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
382,5,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
383,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
383,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
383,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
383,4,Pruritus genital,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
384,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
384,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
385,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
386,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
386,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
386,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
386,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
386,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
387,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
387,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
387,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
387,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
387,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
387,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
388,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
388,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
389,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
389,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
389,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
389,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
390,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
390,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
390,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
390,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
390,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
391,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
391,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
392,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
392,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
393,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
393,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
393,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
393,4,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
394,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
394,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
395,1,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
395,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
396,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
396,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
396,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
396,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
396,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
396,6,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
397,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
397,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
397,3,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
397,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
398,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
399,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
399,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
399,3,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
399,4,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
400,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
400,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
401,1,Idiopathic urticaria,Urticarias,Angioedema and urticaria,Skin,N
402,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
402,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
402,3,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
403,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
404,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
404,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
404,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
405,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
405,2,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
406,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
406,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
406,3,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
407,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
407,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
407,3,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
408,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
408,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
409,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
410,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
411,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
411,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
411,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
411,4,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
411,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
411,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
412,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
412,2,Device physical property issue,Device physical property and chemical issues,Device issues,Prod,N
413,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
413,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
413,3,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
413,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
413,5,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
414,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
414,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
414,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
415,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
415,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
415,3,Koebner phenomenon,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
415,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
416,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
416,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
416,3,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
417,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
418,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
418,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
418,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
418,4,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
419,1,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
420,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
420,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
420,3,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
420,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
421,1,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
421,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
421,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
422,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
422,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
422,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
422,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
422,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
423,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
423,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
423,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
423,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
424,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
424,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
425,1,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
425,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
425,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
425,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
425,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
425,6,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
426,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
426,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
426,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
427,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
428,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
428,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
429,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
429,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
430,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
430,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
430,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
430,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
431,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
431,2,Device leakage,Device issues NEC,Device issues,Prod,N
431,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
432,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
432,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
432,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
432,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
433,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
433,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
433,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
434,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
434,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
435,1,Product label issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
435,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
436,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
437,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
437,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
438,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
438,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
438,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
439,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
439,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
439,3,Oral mucosal exfoliation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
439,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
440,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
441,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
441,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
441,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
442,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
442,2,Device issue,Device issues NEC,Device issues,Prod,N
442,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
442,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
443,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
443,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
444,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
444,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
444,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
445,1,Device difficult to use,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
445,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
445,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
445,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
446,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
447,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
447,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
447,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
448,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
448,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
448,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
449,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
449,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
449,3,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
449,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
449,5,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
449,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
450,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
450,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
450,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
450,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
451,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
452,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
452,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
453,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
454,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
454,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
455,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
455,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
455,3,Eructation,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
455,4,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
455,5,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
455,6,Hyperchlorhydria,Gastrointestinal mucosal dystrophies and secretion disorders,Gastrointestinal conditions NEC,Gastr,N
455,7,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
455,8,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
455,9,Loss of control of legs,Gait disturbances,General system disorders NEC,Genrl,N
455,10,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
455,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
456,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
457,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
458,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
458,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
458,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
459,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
459,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
459,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
460,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
461,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
461,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
462,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
462,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
462,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
463,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
463,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
463,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
463,4,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
463,5,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
464,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
464,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
464,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
464,4,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
464,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
465,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
465,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
465,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
466,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
466,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
467,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
467,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
468,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
468,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
468,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
469,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
470,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
470,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
470,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
471,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
472,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
472,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
473,1,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
474,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
475,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
476,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
476,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
476,3,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
476,4,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
477,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
478,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
478,2,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
479,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
480,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
480,2,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
481,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
482,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
482,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
483,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
483,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
484,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
484,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
485,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
485,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
485,3,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
486,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
486,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
486,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
487,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
487,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
487,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
488,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
488,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
489,1,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
490,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
491,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
492,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
492,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
493,1,Blindness transient,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
493,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
493,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
493,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
493,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
494,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
494,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
495,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
495,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
495,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
495,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
495,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
495,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
495,7,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
495,8,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
495,9,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
496,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
496,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
497,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
497,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
497,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
498,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
498,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
498,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
498,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
498,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
499,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
499,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
499,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
499,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
500,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
501,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
501,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
502,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
503,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
504,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
505,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
505,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
505,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
505,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
506,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
506,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
507,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
508,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
508,2,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
508,3,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
508,4,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
508,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
508,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
509,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
509,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
509,3,Pancreatitis relapsing,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
509,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
510,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
511,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
511,2,Headache,Headaches NEC,Headaches,Nerv,N
511,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
512,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
512,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
512,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
512,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
513,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
513,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
513,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
513,4,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
513,5,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
514,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
515,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
515,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
515,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
516,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
516,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
516,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
517,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
518,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
519,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
519,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
519,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
520,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
520,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
520,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
520,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
521,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
521,2,Headache,Headaches NEC,Headaches,Nerv,N
521,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
521,4,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
521,5,Panic disorder,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
521,6,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
522,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
523,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
524,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
524,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
525,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
526,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
526,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
526,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
526,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
527,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
527,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
527,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
527,4,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
528,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
528,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
528,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
528,4,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
528,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
528,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
528,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
529,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
529,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
529,3,Product tampering,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
530,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
530,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
530,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
531,1,Diabetic complication,Diabetic complications NEC,Diabetic complications,Metab,N
531,2,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
532,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
533,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
533,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
533,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
534,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
534,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
535,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
535,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
535,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
536,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
537,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
538,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
538,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
538,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
538,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
539,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
540,1,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
540,2,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
540,3,Ocular neoplasm,Ocular neoplasms malignancy unspecified,Ocular neoplasms,Neopl,N
541,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
541,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
541,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
542,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
542,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
542,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
543,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
543,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
544,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
545,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
545,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
546,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
546,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
546,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
546,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
547,1,Age-related macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
547,2,Aneurysm,Aneurysms and dissections non-site specific,Aneurysms and artery dissections,Vasc,N
547,3,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
547,4,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
547,5,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
548,1,Cervical vertebral fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
548,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
548,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
549,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
549,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
549,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
550,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
551,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
551,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
552,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
552,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
553,1,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
553,2,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
553,3,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
554,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
554,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
555,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
555,2,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
555,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
555,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
556,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
557,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
558,1,Device issue,Device issues NEC,Device issues,Prod,N
558,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
558,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
559,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
559,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
559,3,Device issue,Device issues NEC,Device issues,Prod,N
559,4,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
559,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
559,6,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
560,1,Device issue,Device issues NEC,Device issues,Prod,N
560,2,Device issue,Device issues NEC,Device issues,Prod,N
560,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
561,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
561,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
561,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
562,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
562,2,Device failure,Device issues NEC,Device issues,Prod,N
562,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
562,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
562,5,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
562,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
562,7,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
562,8,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
562,9,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
563,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
563,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
563,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
563,4,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
564,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
565,1,Headache,Headaches NEC,Headaches,Nerv,N
566,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
566,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
566,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
566,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
566,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
566,6,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
566,7,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
566,8,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
567,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
568,1,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
568,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
569,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
569,2,Device issue,Device issues NEC,Device issues,Prod,N
569,3,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
569,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
569,5,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
570,1,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
571,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
571,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
572,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
572,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
573,1,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
573,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
574,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
575,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
575,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
576,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
576,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
577,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
577,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
577,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
577,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
577,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
578,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
579,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
580,1,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
581,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
581,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
581,3,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
581,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
581,5,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
581,6,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
581,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
581,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
581,9,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
581,10,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
582,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
582,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
582,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
582,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
583,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
584,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
584,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
585,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
586,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
586,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
587,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
587,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
587,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
587,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
588,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
588,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
589,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
589,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
589,3,Periarthritis,Joint related disorders NEC,Joint disorders,Musc,N
589,4,Sticky skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
590,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
590,2,Female sexual dysfunction,Sexual function and fertility disorders NEC,Sexual function and fertility disorders,Repro,N
590,3,Rectocele,Pelvic prolapse conditions,"Uterine, pelvic and broad ligament disorders",Repro,N
590,4,Stress urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
591,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
591,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
591,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
592,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
593,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
593,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
593,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
594,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
594,2,Device failure,Device issues NEC,Device issues,Prod,N
595,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
596,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
597,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
598,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
598,2,Type 1 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
599,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
599,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
600,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
600,2,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
600,3,Renal transplant,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
601,1,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
601,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
602,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
602,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
602,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
603,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
603,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
603,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
604,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
604,2,Brachial plexus injury,Peripheral nerve injuries,Injuries NEC,Inj&P,N
604,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
604,4,Diabetic ketosis,Diabetic complications NEC,Diabetic complications,Metab,N
604,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
605,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
605,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
606,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
607,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
608,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
608,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
609,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
609,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
609,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
610,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
610,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
611,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
612,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
612,2,Device issue,Device issues NEC,Device issues,Prod,N
612,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
613,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
613,2,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
613,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
613,4,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
613,5,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
613,6,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
613,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
614,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
614,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
615,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
615,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
616,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
617,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
617,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
618,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
619,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
619,2,Meningitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
620,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
620,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
620,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
620,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
620,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
621,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
622,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
622,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
623,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
623,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
624,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
625,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
626,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
626,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
626,3,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
626,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
626,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
627,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
627,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
628,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
629,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
629,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
629,3,Neuropathic arthropathy,Osteoarthropathies,Joint disorders,Musc,N
630,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
631,1,Knee operation,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
632,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
633,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
634,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
634,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
634,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
635,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
636,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
636,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
637,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
638,1,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
638,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
638,3,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
638,4,Live birth,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
639,1,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
639,2,Live birth,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
639,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
639,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
640,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
640,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
641,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
642,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
642,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
643,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
644,1,Hip surgery,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
645,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
646,1,Device failure,Device issues NEC,Device issues,Prod,N
646,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
646,3,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
647,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
648,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
648,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
648,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
648,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
648,5,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
648,6,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
648,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
648,8,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
649,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
650,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
651,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
652,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
652,2,Device failure,Device issues NEC,Device issues,Prod,N
653,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
653,2,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
653,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
653,4,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
653,5,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
654,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
654,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
654,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
654,4,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
654,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
655,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
655,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
655,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
655,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
656,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
656,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
657,1,Carpal tunnel syndrome,Mononeuropathies,Peripheral neuropathies,Nerv,N
658,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
659,1,Device failure,Device issues NEC,Device issues,Prod,N
659,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
660,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
661,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
661,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
661,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
661,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
661,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
662,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
662,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
662,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
662,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
663,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
663,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
663,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
664,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
664,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
664,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
665,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
665,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
666,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
666,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
667,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
667,2,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
667,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
668,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
668,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
669,1,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
670,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
670,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
670,3,Headache,Headaches NEC,Headaches,Nerv,N
670,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
670,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
671,1,Device failure,Device issues NEC,Device issues,Prod,N
671,2,Organ failure,General signs and symptoms NEC,General system disorders NEC,Genrl,N
672,1,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
673,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
674,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
674,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
675,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
675,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
675,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
675,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
675,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
675,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
676,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
676,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
676,3,Knee operation,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
676,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
677,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
678,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
679,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
679,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
679,3,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
679,4,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
679,5,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
679,6,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
680,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
680,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
681,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
681,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
682,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
682,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
682,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
683,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
683,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
683,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
684,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
685,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
686,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
686,2,Device failure,Device issues NEC,Device issues,Prod,N
686,3,Device leakage,Device issues NEC,Device issues,Prod,N
686,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
686,5,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
687,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
687,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
687,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
687,4,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
687,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
687,6,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
687,7,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
687,8,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
688,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
688,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
688,3,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
688,4,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
689,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
689,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
689,3,Device failure,Device issues NEC,Device issues,Prod,N
689,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
689,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
689,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
689,7,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
689,8,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
690,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
691,1,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
692,1,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
692,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
693,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
693,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
693,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
693,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
693,5,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
693,6,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
693,7,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
693,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
693,9,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
693,10,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
693,11,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
693,12,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
693,13,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
694,1,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
695,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
695,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
696,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
696,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
697,1,Device use error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
697,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
698,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
699,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
700,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
700,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
700,3,Device failure,Device issues NEC,Device issues,Prod,N
700,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
701,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
702,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
702,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
703,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
703,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
703,3,Device defective,Device physical property and chemical issues,Device issues,Prod,N
703,4,Device issue,Device issues NEC,Device issues,Prod,N
703,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
703,6,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
703,7,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
703,8,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
704,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
704,2,Injection site injury,Injection site reactions,Administration site reactions,Genrl,N
705,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
706,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
706,2,Product package associated injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
706,3,Wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
707,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
708,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
708,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
708,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
708,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
709,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
709,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
710,1,Dose calculation error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
710,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
711,1,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
712,1,Pleurisy,Pleural infections and inflammations,Pleural disorders,Resp,N
712,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
713,1,Ankle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
714,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
714,2,Device leakage,Device issues NEC,Device issues,Prod,N
714,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
714,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
714,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
714,6,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
715,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
716,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
716,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
717,1,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
717,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
717,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
718,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
718,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
719,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
720,1,Drug effect faster than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
720,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
721,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
721,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
721,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
721,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
722,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
722,2,Device information output issue,Device information output issues,Device issues,Prod,N
722,3,Device power source issue,Device malfunction events NEC,Device issues,Prod,N
722,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
722,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
722,6,Product dose omission in error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
723,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
724,1,Device information output issue,Device information output issues,Device issues,Prod,N
724,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
724,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
725,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
725,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
726,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
726,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
726,3,Device information output issue,Device information output issues,Device issues,Prod,N
726,4,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
726,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
726,6,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
727,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
728,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
728,2,Mast cell activation syndrome,Haematological disorders,Haematological disorders NEC,Blood,N
729,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
729,2,Device occlusion,Device malfunction events NEC,Device issues,Prod,N
729,3,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
729,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
729,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
730,1,Retinal tear,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
731,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
731,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
732,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
732,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
732,3,Grief reaction,Adjustment disorders,Adjustment disorders (incl subtypes),Psych,N
732,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
732,5,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
733,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
733,2,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
733,3,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
733,4,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
733,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
733,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
733,7,Streptococcal sepsis,Streptococcal infections,Bacterial infectious disorders,Infec,N
734,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
734,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
735,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
735,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
736,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
736,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
737,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
737,2,Device leakage,Device issues NEC,Device issues,Prod,N
737,3,Drug dose omission by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
737,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
738,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
738,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
739,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
739,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
740,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
740,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
741,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
742,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
742,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
742,3,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
743,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
743,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
743,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
743,4,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
744,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
744,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
745,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
745,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
745,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
746,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
747,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
748,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
748,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
748,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
748,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
748,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
749,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
749,2,Device failure,Device issues NEC,Device issues,Prod,N
749,3,Incorrect dose administered by product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
750,1,Blood insulin abnormal,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
750,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
750,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
751,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
752,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
753,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
753,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
753,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
754,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
754,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
755,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
755,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
755,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
755,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
755,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
755,6,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
755,7,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
755,8,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
755,9,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
755,10,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
755,11,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
756,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
756,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
756,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
757,1,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
757,2,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
757,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
758,1,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
758,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
759,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
759,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
760,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
761,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
761,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
762,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
763,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
763,2,Headache,Headaches NEC,Headaches,Nerv,N
763,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
764,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
764,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
765,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
765,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
765,3,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
765,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
766,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
766,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
766,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
767,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
767,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
767,3,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
767,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
767,5,Subcutaneous drug absorption impaired,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
768,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
769,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
769,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
769,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
769,4,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
769,5,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
769,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
769,7,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
770,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
770,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
771,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
772,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
773,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
773,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
773,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
773,4,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
774,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
774,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
774,3,Device issue,Device issues NEC,Device issues,Prod,N
774,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
775,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
776,1,Cancer surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
777,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
778,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
779,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
780,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
781,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
782,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
782,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
783,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
784,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
785,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
785,2,Chondropathy,Cartilage disorders,"Tendon, ligament and cartilage disorders",Musc,N
786,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
786,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
786,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
787,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
788,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
788,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
789,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
790,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
790,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
790,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
791,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
792,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
792,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
793,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
794,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
795,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
796,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
797,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
797,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
797,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
798,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
798,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
798,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
798,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
798,5,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
798,6,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
798,7,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
799,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
799,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
799,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
799,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
800,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
800,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
800,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
800,4,Renal injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
800,5,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
801,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
802,1,Device failure,Device issues NEC,Device issues,Prod,N
802,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
802,3,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
803,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
804,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
804,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
804,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
805,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
806,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
806,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
806,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
807,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
807,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
807,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
808,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
809,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
809,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
809,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
810,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
811,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
811,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
811,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
811,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
811,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
812,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
813,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
813,2,Device failure,Device issues NEC,Device issues,Prod,N
813,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
814,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
814,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
814,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
815,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
815,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
815,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
816,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
816,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
817,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
818,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
818,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
818,3,Device issue,Device issues NEC,Device issues,Prod,N
818,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
818,5,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
818,6,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
819,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
819,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
819,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
820,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
820,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
820,3,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
820,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
821,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
822,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
